SCHEMBL18282157

SCHEMBL18282157

COC(=O)c1c(-c2cc(C)nc(C)c2)c(C)nn1-c1nc(-c2ccc(C(F)(F)F)cc2)c(SC(C)C)s1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 2/20 0.35
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GAA P10253 1/20 0.32
SLC34A1 Q06495 1/20 0.32
FFAR1 O14842 2/20 0.32
PPARD Q03181 3/20 0.32
PPARA Q07869 3/20 0.32
DHODH Q02127 1/20 0.31
SCN9A Q15858 1/20 0.31
HSP90AA1 P07900 1/20 0.31
CRHBP P24387 1/20 0.31
CRHR2 Q13324 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18282156 0.92 NPC1 (0.37) NPC1SMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL18282045 0.89 MYC (0.36) NPC1SMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL18282084 0.89 MEN1 (0.38) SMN1; SMN2MAPTALDH1A1KDM4EMEN1
SCHEMBL18282276 0.89 KDM4E (0.36) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL18282149 0.87 ALDH1A1 (0.34) NPC1SMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL18281998 0.85 XIAP (0.32) MAPTKDM4E
SCHEMBL18295313 0.85 MAPT (0.36) NPC1SMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL18282002 0.85 TDP1 (0.34) MAPTALDH1A1KMT2AL3MBTL1
SCHEMBL18282183 0.84
SCHEMBL18282268 0.84 FNTA (0.42) SMN1; SMN2MAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12150934-B2 Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases BANTAM PHARMACEUTICAL, LLC (US) 2024-11-26 US disclosed
US-11602526-B2 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto BANTAM PHARMACEUTICAL, LLC (US) 2023-03-14 US disclosed
US-20200261424-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto BANTAM PHARMACEUTICAL, LLC 2020-08-20 US disclosed
US-20200069656-A1 Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases BANTAM PHARMACEUTICAL, LLC 2020-03-05 US disclosed
CN-110769823-A Methods of using substituted pyrazole and pyrrole compounds and treating hyperproliferative diseases 班塔姆制药有限责任公司 2020-02-07 CN disclosed
EP-3548024-A2 METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES Bantam Pharmaceutical, LLC (US) 2019-10-09 EP disclosed
US-20180311218-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EGENIX, INC. 2018-11-01 US disclosed
WO-2018102452-A2 METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES BANTAM PHARMACEUTICAL, LLC (US) 2018-06-07 WO disclosed
EP-3303332-A1 SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO Bantam Pharmaceutical, LLC (US) 2018-04-11 EP disclosed
WO-2016196644-A1 SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO BANTAM PHARMACEUTICAL, LLC (US) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200261424-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EIF4A1, EIF4A3, EIF4B NPC1 4050/4885SMN1; SMN2 548/4885MAPT 2284/4885
US-20180311218-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EIF4A3, EIF4A1, EIF4B NPC1 4643/4885SMN1; SMN2 711/4885MAPT 2855/4885
US-20200069656-A1 Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases KRAS, TP53, CCNA1 NPC1 4164/4885SMN1; SMN2 4279/4885MAPT 4869/4885
US-12150934-B2 Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases KRAS, TP53, CCNA1 NPC1 4164/4885SMN1; SMN2 4279/4885MAPT 4869/4885
US-11602526-B2 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto EIF4A1, EIF4A3, EIF4B NPC1 4050/4885SMN1; SMN2 548/4885MAPT 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.